Literature DB >> 2916633

Prednisone does not prevent recurrent fetal death in women with antiphospholipid antibody.

M D Lockshin1, M L Druzin, T Qamar.   

Abstract

Effects of therapy, antibody titer, and pregnancy history on pregnancy outcome were evaluated in pregnancies of women with antiphospholipid antibody. Prior fetal death and a high antiphospholipid antibody titer (greater than 40 IgG phospholipid units) contributed independently, in an additive manner, to current fetal loss. Twenty-one pregnancies occurred in asymptomatic women who had both prior fetal death and a high IgG antiphospholipid antibody titer. In this very high-risk group, 9 of 11 (82%) of pregnancies treated with prednisone, 10 to 60 mg/day, ended in fetal death, compared with 5 of 10 (50%) not treated with prednisone (p approximately 0.01, life-table analysis). Of pregnancies treated with aspirin, 80 mg/day, 9 of 14 (64%) treated and 5 of 7 (71%) not treated with prednisone had a fetal death (difference not significant). Prednisone does not improve, and may worsen, current fetal outcome in asymptomatic pregnant women with a high antiphospholipid antibody titer and prior fetal death.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2916633     DOI: 10.1016/0002-9378(89)90468-7

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  23 in total

1.  Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies.

Authors:  T Jonsdottir; J Forslid; A van Vollenhoven; A Harju; S Brannemark; L Klareskog; R F van Vollenhoven
Journal:  Ann Rheum Dis       Date:  2004-04-05       Impact factor: 19.103

2.  Management of the antiphospholipid syndrome.

Authors:  M A Khamashta; T Wallington
Journal:  Ann Rheum Dis       Date:  1991-12       Impact factor: 19.103

Review 3.  Treatment of the antiphospholipid syndrome.

Authors:  J C Piette; M Karmochkine; T Papo; L T Du; C Francès; B Wechsler
Journal:  Clin Rev Allergy Immunol       Date:  1995       Impact factor: 8.667

4.  Management of antiphospholipid syndrome.

Authors:  Nicoletta Del Papa; Nikoleta Vaso
Journal:  Ther Adv Musculoskelet Dis       Date:  2010-08       Impact factor: 5.346

Review 5.  Anticardiolipin antibodies and cardiovascular disease.

Authors:  K W Muir
Journal:  J R Soc Med       Date:  1995-08       Impact factor: 5.344

Review 6.  Systemic lupus erythematosus--disease management.

Authors:  M F Gourley
Journal:  Springer Semin Immunopathol       Date:  1994

Review 7.  Lupus pregnancies and neonatal lupus.

Authors:  M D Lockshin
Journal:  Springer Semin Immunopathol       Date:  1994

Review 8.  Antiphospholipid antibodies and the antiphospholipid syndrome.

Authors:  E N Harris; S S Pierangeli
Journal:  Springer Semin Immunopathol       Date:  1994

9.  Monoclonal anticardiolipin antibodies derived from mice with experimental lupus erythematosus: characterization and the induction of a secondary antiphospholipid syndrome.

Authors:  Z M Sthoeger; B Tartakovsky; Z Bentwich; E Mozes
Journal:  J Clin Immunol       Date:  1993-03       Impact factor: 8.317

Review 10.  Anticoagulation in management of antiphospholipid antibody syndrome in pregnancy.

Authors:  Michael D Lockshin
Journal:  Clin Lab Med       Date:  2013-04-19       Impact factor: 1.935

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.